These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 17667921)

  • 21. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas.
    Puxeddu E; Moretti S; Elisei R; Romei C; Pascucci R; Martinelli M; Marino C; Avenia N; Rossi ED; Fadda G; Cavaliere A; Ribacchi R; Falorni A; Pontecorvi A; Pacini F; Pinchera A; Santeusanio F
    J Clin Endocrinol Metab; 2004 May; 89(5):2414-20. PubMed ID: 15126572
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of HIF-1α and HIF-2α correlates to biological and clinical significance in papillary thyroid carcinoma.
    Liu YM; Ying SP; Huang YR; Pan Y; Chen WJ; Ni LQ; Xu JY; Shen QY; Liang Y
    World J Surg Oncol; 2016 Feb; 14(1):30. PubMed ID: 26846782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overexpression of estrogen receptor-α in human papillary thyroid carcinomas studied by laser- capture microdissection and molecular biology.
    Di Vito M; De Santis E; Perrone GA; Mari E; Giordano MC; De Antoni E; Coppola L; Fadda G; Tafani M; Carpi A; Russo MA
    Cancer Sci; 2011 Oct; 102(10):1921-7. PubMed ID: 21707866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. AEG-1 associates with metastasis in papillary thyroid cancer through upregulation of MMP2/9.
    Huang LL; Wang Z; Cao CJ; Ke ZF; Wang F; Wang R; Luo CQ; Lu X; Wang LT
    Int J Oncol; 2017 Sep; 51(3):812-822. PubMed ID: 28731152
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thyrospheres From Normal or Malignant Thyroid Tissue Have Different Biological, Functional, and Genetic Features.
    Gianì F; Vella V; Nicolosi ML; Fierabracci A; Lotta S; Malaguarnera R; Belfiore A; Vigneri R; Frasca F
    J Clin Endocrinol Metab; 2015 Sep; 100(9):E1168-78. PubMed ID: 26151334
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The loss of the p53 activator HIPK2 is responsible for galectin-3 overexpression in well differentiated thyroid carcinomas.
    Lavra L; Rinaldo C; Ulivieri A; Luciani E; Fidanza P; Giacomelli L; Bellotti C; Ricci A; Trovato M; Soddu S; Bartolazzi A; Sciacchitano S
    PLoS One; 2011; 6(6):e20665. PubMed ID: 21698151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.
    Romei C; Ciampi R; Faviana P; Agate L; Molinaro E; Bottici V; Basolo F; Miccoli P; Pacini F; Pinchera A; Elisei R
    Endocr Relat Cancer; 2008 Jun; 15(2):511-20. PubMed ID: 18509003
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of nicotinamide adenine dinucleotide phosphate oxidase flavoprotein DUOX genes and proteins in human papillary and follicular thyroid carcinomas.
    Lacroix L; Nocera M; Mian C; Caillou B; Virion A; Dupuy C; Filetti S; Bidart JM; Schlumberger M
    Thyroid; 2001 Nov; 11(11):1017-23. PubMed ID: 11762710
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of ret/PTC-1 rearrangements in neoplastic thyroid tissue using TaqMan RT-PCR.
    Sheils OM; O'Leary JJ; Sweeney EC
    J Pathol; 2000 Sep; 192(1):32-6. PubMed ID: 10951397
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long Non-coding RNA Expression in Anaplastic Thyroid Carcinomas.
    Wang Y; Hardin H; Chu YH; Esbona K; Zhang R; Lloyd RV
    Endocr Pathol; 2019 Dec; 30(4):262-269. PubMed ID: 31468286
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In situ detection of hTERT mRNA relates to Ki-67 labeling index in papillary thyroid carcinoma.
    Chou SJ; Chen CM; Harn HJ; Chen CJ; Liu YC
    J Surg Res; 2001 Jul; 99(1):75-83. PubMed ID: 11421607
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ret/PTC activation does not influence clinical and pathological features of adult papillary thyroid carcinomas.
    Puxeddu E; Moretti S; Giannico A; Martinelli M; Marino C; Avenia N; Cristofani R; Farabi R; Reboldi G; Ribacchi R; Pontecorvi A; Santeusanio F
    Eur J Endocrinol; 2003 May; 148(5):505-13. PubMed ID: 12720532
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NATH, a novel gene overexpressed in papillary thyroid carcinomas.
    Fluge Ø; Bruland O; Akslen LA; Varhaug JE; Lillehaug JR
    Oncogene; 2002 Aug; 21(33):5056-68. PubMed ID: 12140756
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent and -independent mechanisms.
    Nicolussi A; D'Inzeo S; Mincione G; Buffone A; Di Marcantonio MC; Cotellese R; Cichella A; Capalbo C; Di Gioia C; Nardi F; Giannini G; Coppa A
    Int J Oncol; 2014 Feb; 44(2):548-56. PubMed ID: 24316730
    [TBL] [Abstract][Full Text] [Related]  

  • 35. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan.
    Liu RT; Chen YJ; Chou FF; Li CL; Wu WL; Tsai PC; Huang CC; Cheng JT
    Clin Endocrinol (Oxf); 2005 Oct; 63(4):461-6. PubMed ID: 16181240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studies.
    Muzza M; Degl'Innocenti D; Colombo C; Perrino M; Ravasi E; Rossi S; Cirello V; Beck-Peccoz P; Borrello MG; Fugazzola L
    Clin Endocrinol (Oxf); 2010 May; 72(5):702-8. PubMed ID: 20447069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma.
    Rhoden KJ; Unger K; Salvatore G; Yilmaz Y; Vovk V; Chiappetta G; Qumsiyeh MB; Rothstein JL; Fusco A; Santoro M; Zitzelsberger H; Tallini G
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2414-23. PubMed ID: 16595592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An Ep-ICD based index is a marker of aggressiveness and poor prognosis in thyroid carcinoma.
    He HC; Kashat L; Kak I; Kunavisarut T; Gundelach R; Kim D; So AK; MacMillan C; Freeman JL; Ralhan R; Walfish PG
    PLoS One; 2012; 7(9):e42893. PubMed ID: 23049733
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cellular apoptosis susceptibility (CAS) is overexpressed in thyroid carcinoma and maintains tumor cell growth: A potential link to the BRAFV600E mutation.
    Holzer K; Drucker E; Oliver S; Winkler J; Eiteneuer E; Herpel E; Breuhahn K; Singer S
    Int J Oncol; 2016 Apr; 48(4):1679-87. PubMed ID: 26892809
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long Non-coding RNA Linc-ROR Is Upregulated in Papillary Thyroid Carcinoma.
    Zhang R; Hardin H; Huang W; Buehler D; Lloyd RV
    Endocr Pathol; 2018 Mar; 29(1):1-8. PubMed ID: 29280051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.